Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection

Hye Won Lee, Jun Yong Park, Taegon Hong, Min Soo Park, Sang Hoon Ahn

Research output: Contribution to journalShort surveypeer-review

4 Citations (Scopus)

Abstract

The mechanism of action of hepatitis B immunoglobulin (HBIG) for chronic hepatitis B (CHB) treatment is not fully understood. A clinical trial in Japan suggested that HBIG therapy might benefit patients with CHB.1 Lenvervimab, a recombinant monoclonal HBIG developed by GC Pharma (Yongin, South Korea), has been screened from an anti–HBs-enriched phage-display library cloned from hepatitis B vaccine-boosted human blood cells and was produced in Chinese hamster ovary cells.2–4

Original languageEnglish
Pages (from-to)3043-3045.e1
JournalClinical Gastroenterology and Hepatology
Volume18
Issue number13
DOIs
Publication statusPublished - 2020 Dec

Bibliographical note

Funding Information:
Conflicts of interest This author discloses the following: S.H.A. has acted as advisor and lecturer for BMS, Gilead Sciences, MSD, AbbVie, Janssen, Assembly Biosciences, Arbutus Biopharma, GC pharma, and Ildong and has received unrestricted grant from Gilead Sciences for the investigator initiated trials. The remaining authors disclose no conflicts. Funding Supported by GC Pharma Co Ltd.

Funding Information:
Funding Supported by GC Pharma Co Ltd.

Publisher Copyright:
© 2020 AGA Institute

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Fingerprint

Dive into the research topics of 'Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection'. Together they form a unique fingerprint.

Cite this